Jazz Pharmaceuticals Files 8-K Amendment

Ticker: JAZZ · Form: 8-K/A · Filed: Mar 5, 2025 · CIK: 1232524

Jazz Pharmaceuticals PLC 8-K/A Filing Summary
FieldDetail
CompanyJazz Pharmaceuticals PLC (JAZZ)
Form Type8-K/A
Filed DateMar 5, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: amendment, material-agreement, filing

TL;DR

Jazz Pharma filed an 8-K amendment on a material agreement. Check for updates.

AI Summary

Jazz Pharmaceuticals plc filed an amendment (8-K/A) on March 5, 2025, to a previous filing concerning a material definitive agreement entered into on March 4, 2025. The filing also includes Regulation FD disclosures and financial statements/exhibits.

Why It Matters

This amendment provides updated or supplementary information regarding a significant agreement, which could impact investors' understanding of the company's strategic direction and financial commitments.

Risk Assessment

Risk Level: medium — Amendments to material definitive agreements can signal changes in business operations or financial arrangements that may carry inherent risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K/A filing?

The primary purpose is to amend a previous filing related to the entry into a material definitive agreement, and to include Regulation FD disclosures and financial statements/exhibits.

When was the earliest event reported in this filing?

The earliest event reported was on March 4, 2025.

What is the filing date of this amendment?

This amendment was filed on March 5, 2025.

What is the company's principal executive office address?

The company's principal executive offices are located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

What is the company's Standard Industrial Classification (SIC) code?

The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K/A (Form 8-K/A) was filed with the SEC on March 5, 2025 regarding Jazz Pharmaceuticals plc (JAZZ).

View full filing on EDGAR

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on Read The Filing